Ractigen Therapeutics has received FDA clearance for RAG-01, a pioneering saRNA treatment for NMIBC that does not respond to BCG.

U.S. FDA Sanctions Single-Dose Gene Treatment BEQVEZ™ (fidanacogene elaparvovec-dzkt) by Pfizer for Adult Hemophilia B Patients.

Advanced gastrointestinal cancer patients continue to test dosages with the novel T-cell engager, CDH17 X CD3 cabotamig (ARB202).

Cidara Therapeutics regains worldwide control for developing and marketing CD388, also launches a $240 million private funding initiative.

FDA has prioritized GSK’s submission to broaden the use of Jemperli (dostarlimab) with chemotherapy for treating all adult patients with initial advanced or relapsed endometrial cancer.

Alkermes plc has launched the Vibrance-1 study, a phase 2 clinical trial aimed at assessing the safety and effectiveness of ALKS 2680 versus a placebo in individuals diagnosed with type 1 narcolepsy.

Atom Bioscience focused on innovative therapies for metabolic and inflammatory conditions, has initiated patient enrollment across the United States for a Phase 2b/3 study of ABP-671.

Endeavor BioMedicines has successfully secured $132.5 million in an oversubscribed Series C funding round to progress their groundbreaking medical pipeline.

Arrowhead Pharmaceuticals has started a Phase 1/2a trial for ARO-CFB aimed at treating kidney diseases caused by complement system dysfunctions.

The FDA has approved Novartis's radioligand treatment, Lutathera®, as the initial specific drug for young patients with neuroendocrine tumors of the gastroenteropancreatic area.

European Commission approves Astellas' XTANDI™ (Enzalutamide) for expanded use in recurrent early-stage prostate cancer treatment.

CSL Vifor and Travere Therapeutics Report European Commission's Approval of FILSPARI® (sparsentan) for IgA Nephropathy Treatment.